Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines

• Spencer D. Martin,

  Affiliations Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada, Interdisciplinary Oncology Program, University of British Columbia, Vancouver, Canada, Michael Smith’s Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, Canada

  http://orcid.org/0000-0001-5914-0305

  ⨯
• Scott D. Brown,

  Affiliation Michael Smith’s Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, Canada

  ⨯
• Darin A. Wick,

  Affiliation Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada

  ⨯
• Julie S. Nielsen,

  Affiliation Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada

  ⨯
• David R. Kroeger,

  Affiliation Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada

  ⨯
• Kwame Twumasi-Boateng,

  Affiliation Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada

  ⨯
• Robert A. Holt,

  Affiliations Michael Smith’s Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, Canada, Molecular Biology and Biochemistry, Simon Fraser University, Vancouver, Canada, Department of Medical Genetics, University of British Columbia, Vancouver, Canada

  ⨯
• Brad H. Nelson

  * E-mail: bnelson@bccrc.ca

  Affiliations Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada, Department of Medical Genetics, University of British Columbia, Vancouver, Canada, Department of Microbiology and Biochemistry, University of Victoria, Victoria, Canada

  ⨯